Oncology
Myelofibrosis
Expert Roundtables Podcast: Myelofibrosis – Frontiers and Future Directions
Overview
<p>An improved understanding of genetics and disease mechanisms in myelofibrosis has spurred the development of newer therapeutic strategies. Promising research includes exploration of novel JAK2-specific approaches as well as mutant CALR-directed immunotherapy.</p>
<p> </p>
<p> </p>
<p><iframe title="Conference Reporter Expert Perspectives® in Myelofibrosis Podcast 2025" width="500" height="281" src="https://www.youtube.com/embed/7BiQm5jxubw?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe></p>
References
Masubuchi N, Yang Y, Imai M, et al. Loss of KDEL function from a calreticulin frameshift mutation drives expression of an immature, mutant calreticulin-dependent form of the thrombopoietin receptor MPL. Haematologica. Published online November 6, 2025. doi:10.3324/haematol.2025.287585
Reis ES, Buonpane R, Celik H, et al. Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN. Blood. 2024;144(22):2336-2348. doi:10.1182/blood.2024024373
Reynolds SB, Komrokji R, Kuykendall AT. The ongoing challenges of managing cytopenic myelofibrosis in 2025: The emergence of non-JAK inhibitor therapies. Blood Lymphat Cancer. 2025;15:181-192. Published 2025 Sep 24. doi:10.2147/BLCTT.S549533
